TmGPC2 01 CAR-T / The Children’s Hospital of Philadelphia, University of Pennsylvania, Gilead - LARVOL DELTA

22CT012: GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: Stephan Grupp MD PhD | N=30 ➔ 45

Enrollment change • Eye Cancer • Neuroblastoma • Oncology • Retinal Disorders • Retinoblastoma • Solid Tumor

D3-GPC2-directed CAR T cells are safe and efficacious in preclinical models of neuroblastoma and small cell lung cancer. (PubMed, Clin Cancer Res) - P1 | "These data validate GPC2 as a bona fide CAR T cell target in neuroblastoma and other cancers. The safety and preliminary efficacy of GPC2 CAR T cells are being tested in a first-in-human phase 1 clinical trial for children with relapsed/refractory neuroblastoma (NCT05650749)."

Journal • Preclinical • Lung Cancer • Neuroblastoma • Oncology • Small Cell Lung Cancer • Solid Tumor • MYCN

22CT012: GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Stephan Grupp MD PhD | Trial completion date: Jan 2026 ➔ Jan 2030 | Trial primary completion date: Jan 2025 ➔ Jan 2028

Trial completion date • Trial primary completion date • CNS Tumor • Neuroblastoma • Oncology • Solid Tumor

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Stephan Grupp MD PhD | Not yet recruiting ➔ Recruiting | Initiation date: Oct 2023 ➔ May 2023

CAR T-Cell Therapy • Enrollment open • Trial initiation date • CNS Tumor • Neuroblastoma • Neuroendocrine Tumor • Oncology • Solid Tumor

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Stephan Grupp MD PhD | Initiation date: Apr 2023 ➔ Oct 2023

CAR T-Cell Therapy • Trial initiation date • CNS Tumor • Neuroblastoma • Neuroendocrine Tumor • Oncology • Solid Tumor

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Stephan Grupp MD PhD | Initiation date: Jan 2023 ➔ Apr 2023

Trial initiation date • CNS Tumor • Neuroblastoma • Neuroendocrine Tumor • Oncology • Solid Tumor

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Stephan Grupp MD PhD

CAR T-Cell Therapy • New P1 trial • CNS Tumor • Neuroblastoma • Neuroendocrine Tumor • Oncology • Solid Tumor